Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al., Treatment and prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer res., 8: 314-346, 2002

Clinical Cancer Research

Volumn 8, Issue 2, 2002, Pages 305-313

  Lippman, Scott M ^a   Waun, Ki Hong ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CELECOXIB; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID; TAMOXIFEN;

ADENOMATOUS POLYP; CANCER PREVENTION; CHEMOPROPHYLAXIS; DRUG EFFECT; DRUG MECHANISM; HUMAN; INTRAEPITHELIAL NEOPLASIA; NONHUMAN; NOTE; PHENOTYPE; PRECANCER; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; HYPERPLASIA; NEOPLASMS; RECEPTORS, ESTROGEN; RETINOIDS; TIME FACTORS;

EID: 0036190840     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (82)

1. Tamoxifen prevention of breast cancer: An instance of the fingerpost
2. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
3. Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development
4. Cancer chemoprevention
5. Cancer chemoprevention: Progress promise
6. Chemoprophylaxis of carcinogenesis: A review
7. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)
8. Rationale and strategies for chemoprevention of cancer in humans
9. The scientific basis for regarding vitamin A and its analogs as anticarcinogenic agents
10. Retinoids and cancer in experimental animals
11. The analysis of cancer chemoprevention experiments
12. Statistical analysis of animal cancer chemoprevention experiments
13. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
14. Is tamoxifen effective in prevention of breast cancer?
15. Breast cancer trial stopped early
16. Genetic alterations during colorectal tumor development
17. Suppression of retinoic acid receptor β in premalignant oral lesions and its up-regulation by isotretinoin
18. Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premalignant lesions and its value in cancer risk assessment
19. Predicting cancer development in oral leukoplakia: Ten years of translational research
20. Molecular markers of the risk of oral cancer
21. Head neck cancer
22. Field cancerization in oral stratified squamous epithelium: Clinical implications of multicentric origin
23. The hallmarks of cancer
24. Cancer chemoprevention in the 21st century: Genetics, risk modeling, and molecular targets
25. Genetic polymorphisms in DNA repair genes and risk of lung cancer
26. A mutator phenotype in cancer
27. Effects of naturally occurring coumarins on the formation of epidermal DNA adducts and skin tumors induced by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in SENCAR mice
28. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer
29. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: A randomised study
30. RecQ helicases and topoisomerases: Components of a conserved complex for the regulation of genetic recombination
31. p53 function and dysfunction
32. Apoptosis in cancer
33. 2 levels in rat colon
34. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac
35. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis
36. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
37. Lipoxygenase modulation to reverse carcinogenesis
38. Chemoprevention of colorectal cancer
39. Protease inhibitors in oral carcinogenesis and chemoprevention
40. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer
41. Recent advances in chemoprevention of cancer
42. Molecular targets for breast cancer therapy and prevention
43. Combinations for cancer prevention
44. A nuclear receptor to prevent colon cancer
45. Prostaglandins and leukotrienes: Advances in cicosanoid biology
46. The influence of margin width on local control of ductal carcinoma in situ of the breast
47. Prophylactic mastectomy - The price of fear
48. Chemoprevention of hereditary ovarian cancer
49. The power of genetics to target surgical prevention
50. Tamoxifen in treatment of intraductal breast cancer: National surgical adjuvant breast and bowel project B-24 randomised controlled trial
51. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer
52. Head neck cancer
53. 13-cis-retinoic acid in the treatment of oral leukoplakia
54. Comparison of low-dose isotretinoin with β-carotene to prevent oral carcinogenesis
55. Low-dose isotretinoin versus β-carotene to prevent oral carcinogenesis: Long-term follow-up
56. p53 and retinoid chemoprevention of oral carcinogenesis
57. Phenotype and genotype in advanced premalignant head and neck lesions after chemopreventive therapy
58. Alteration of p53 gene and protein expression and biochemopreventive therapy in patients with advanced premalignant lesions of the head and neck
59. Combined interferon-α, 13-cisretinoic acid and α-tocopherol in locally advanced head and neck squamous cell carcinoma: Novel bioadjuvant Phase II trial
60. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
61. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck: Long-term follow-up
62. Second malignant tumors in head and neck squamous cell carcinoma: The overshadowing threat for patients with early-stage disease
63. Molecular cytogenetic evidence for multistep tumorigenesis: Implications for risk assessment and early detection
64. Randomized Phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small cell lung cancer
65. Long-term tamoxifen therapy for breast cancer
66. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
67. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer
68. Efficacy of bilateral prophylactic mastectomy in BRCAI and BRCA2 gene mutation carriers
69. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCAI and BRCA2
70. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
71. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori
72. Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors
73. Chemoprevention of breast cancer
74. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: A cost-effectiveness analysis
75. Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp
76. Long-term treatment with sulindac in familial adenomatous polyposis: Is there an actual efficacy in prevention of rectal cancer?
77. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
78. Induction of retinoic acid receptor-β suppresses cyclooxygenase-2 expression in esophageal cancer cells
79. Effect of age on risk of second primary colorectal cancer
80. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model
81. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin
82. Chemoprevention of cancer with retinoids